An introduction to the Marburg virus vaccine consortium, MARVAC
Abstract
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine “MARVAC” consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 13, 2022
- Source ID
- 10.1371/journal.ppat.1010805
Entities
People
- Amy Finan
- Ana María Henao-restrepo
- Andrea Marzi
- Anna N. Honko
- Anthony Griffiths
- Cesar Munoz-fontela
- Christina F Spiropoulou
- Christopher L. Parks
- Courtney Finch
- Courtney Woolsey
- Daniel Wolfe
- David Boucher
- David Safronetz
- Dean Smith
- Demetrius Matassov
- Emily V. Nelson
- Ira M. Longini
- James T. Duworko
- Janet V. Díaz
- Jeffrey Meshulam
- Joan Fusco
- Jocelyn Jakubik
- John M Dye
- Julie Ledgerwood
- Karin Bok
- Kelly L. Warfield
- Kerstin Luhn
- Lauren M. Schwartz
- Lisa Hensley
- Michael A. Egan
- Miles W. Carroll
- Nancy J. Sullivan
- Patricia Fast
- Paul Smock
- Robert W Cross
- Roland Zahn
- Roxana Rustomjee
- Ruth Hunegnaw
- Ruxandra Draghia-akli
- Stephan Becker
- Stephan Gunther
- Thomas R. Fleming
- Thomas W Geisbert
- William E. Dowling
- Ydrissa Sow
Organizations
- Biomedical Advanced Research and Development Authority
- Defense Threat Reduction Agency
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- German Center for Infection Research
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health